#United States #New York #Class Action #Levi & Korsinsky #Sana Biotechnology

Class Action Lawsuit Against Sana Biotechnology, Inc.

Introduction
On April 18, 2025, Levi & Korsinsky, LLP reached out to investors of Sana Biotechnology, Inc. (NASDAQ: SANA) to raise awareness about a class action lawsuit concerning the company. This legal action seeks to address potential securities fraud that may have resulted in significant financial losses among shareholders. Investors are urged to take note of the deadlines associated with this case and their rights as shareholders.

Lawsuit Background

The class action lawsuit includes allegations that the defendants made false statements or omitted crucial information regarding the company's financial health and product potential. These claims cover the period from March 17, 2023, to November 4, 2024. Specifically, the lawsuit claims that:
1. Sana was significantly at risk of running out of funds to support its operations and develop its product candidates.
2. Key products, including SC291 in oncology, SC379, and SG299, were less promising than initially suggested, raising concerns over their viability.
3. To preserve cash flow and prioritize more feasible products, Sana was likely to cut funding for or even discontinue work on SC291 in oncology, SC379, and SG299. Such measures would potentially lead to considerable job losses.
4. Consequently, the defendants overstated Sana's financial robustness and capacity to further its projects.

These representations were allegedly misleading and did not provide an accurate picture of the company's condition, creating a false sense of security among investors.

Next Steps for Investors

Any investors who suffered losses associated with Sana Biotechnology from the specified timeframe have until May 20, 2025, to request appointment as lead plaintiff in the lawsuit. It's important to note that participating in this action does not require being a lead plaintiff to be eligible for potential compensation. If you are included, there are no out-of-pocket costs—litigation expenses are typically covered by the law firm.

Levi & Korsinsky's Expertise

Levi & Korsinsky has over 20 years of experience in securities litigation and has successfully recovered hundreds of millions for shareholders in similar situations. With a dedicated team of professionals, the firm has been placed among the top securities litigation firms in the U.S. for seven consecutive years by ISS Securities Class Action Services.

Investors can rest assured that they will be working with a firm committed to advocating for their rights and pursuing the highest standards of justice in securities matters.

Conclusion

As an investor in Sana Biotechnology, you are encouraged to review your involvement and consider your next steps regarding this class action lawsuit. For more information, potential claimants can contact Levi & Korsinsky at the coordinates provided, ensuring they secure their rights and the potential for compensation under the law.

For inquiries, you may reach out to Joseph E. Levi, Esq. at (212) 363-7500 or by email at [email protected]. More detailed information can also be found on their dedicated website linked in their announcement.

Contact Information

• - Levi & Korsinsky, LLP

33 Whitehall Street, 17th Floor
New York, NY 10004
Phone: (212) 363-7500
Email: [email protected]
Website: www.zlk.com

Stay informed, protect your investments, and ensure your voice is heard in matters of corporate accountability.